Healthcare
Riverside's Orliman buys Soft Medical Europe
Riverside bought Orliman in 2011, anticipating a buy-and-build strategy
Calculus participates in £6m Collagen injection
Business has used the funding to buy New Zealand-based Southern Light
Elysian makes 2.6x return on IPS sale
Beechbrook Capital supplied mezzanine and equity investment
Alto invests in listed Novacyt
Company is listed on the Alternext Paris with a market cap of €33m
LDC’s Quantum floats with £125m market cap
GP has retained an 8.2% shareholding following IPO
Optomeditech raises $2.5m from Lifeline and Sitra
Company is preparing for its commercial launch
Equita purchases Windstar Medical
Equita used its Equita Holding and Equita CoVest vehicles to complete the deal
Advent in partial exit from Mediq
GP took Mediq private for €775m at the beginning of 2013
Industrifonden in SEK 42m round for Glionova
Funding round brings total amount raised to nearly SEK 50m
Over the counter deals going over private equity's head
Given the high levels of pharmaceutical OTC deals witnessed in the corporate space this year, is PE missing out?
Cambridge Innovation invests up to £1m in Congenica
Investment will allow company to speed up production of Spienta technology
BioMedPartners and Grazia back Ayoxxa
Additional investment brings funding round to €11.3m
Principia holds first close on €160m
VC's third vehicle has a target of €400-500m
Ascendis completes $60m series-D
A total of seven investors comitted capital to the round
Seed Capital and Novo exit Contera
Exit includes future contingent and royalty payments clause
OEP acquires Duran Group
Vendor Adcuram bought company in 2005 in corporate carve-out
Ippon’s Midatech to float
Ippon is currently the company's second-largest shareholder
LDC's Quantum to float on AIM
Business intends to raise £106.1m through IPO
Pieris raises fifth funding round
Company previously raised €43m in growth capital
LSP-HEF co-leads Curetis’s series-B extension
Molecular diagnostics company has raised €63.5m since inception
Vesalius et al. invest €20m in Promethera
Company recently completed phase-I/II trials of its HepaStem product
HTGF backs PS Biotech
HTGF has backed industrial biotech provider since its spinout in 2013
Imperial et al. invest £50m in Cell Medica
Brings total amount raised by company to £72.5m
Gimv et al. exit listed Prosensa
Sale resulted in 4.6x return on historial investment cost for Gimv